Cancer Patients Cumulatively Saved Around Rs 294 Crore Due To Price Control: JP Nadda

New Delhi: The government makes all efforts to ensure affordable and accessible treatment is available for cancer patients amid a rise in cases in India, Health Minister JP Nadda said on Friday.

Replying to supplementary questions during Question Hour in the Lok Sabha, Nadda said the government made all efforts to ensure that affordable and accessible treatment was available to the patients.

“The number of cancer cases is going up, it is increasing by almost 2.5 per cent every year,” Nadda said.

In men, cases of oral and lung cancer are on the up while more women are getting breast cancer, he added.

More than 1.55 million cancer cases are being registered every year, Nadda said.

“There is a list of 131 essential cancer medicines, which are in Schedule 1, (that) are monitored and (their) pricing is decided by the government. These are the commonly used medicines,” Nadda said.

He said patients cumulatively saved around Rs 294 crore due to this price control.

“There are 28 combinations, which are not in this list but the NPPA (National Pharmaceutical Pricing Authority) and the government have controlled their pricing as well,” he said.

“We have tried to make cancer drugs affordable,” he added.

Responding to another question on healthcare infrastructure, Nadda said the government was apprised of the matter and expansion of medical colleges were happening so that there could be more doctors.

“There should be a balance in quality and quantity of medical education. We are trying to go as fast as we can but, at the same time, (we) do not want to compromise on the quality of medical doctors,” he said.

Nadda informed the House that the number of medical colleges had gone up from 387 in 2014 to 731 at present while the number of MBBS seats rose from 51,348 seats to 1,12,112 (1.12 lakh) during the same period.

The number of postgraduate seats for medical students has gone up from 31,185 in 2014 to 72,627 at present, he added.

Related Posts

Nearly Three in Ten Products in Indian Local Markets Perceived as Counterfeit; Pharmaceuticals and FMCG among Worst-Affected Sectors: ASPA–CRISIL Intelligence Report

New Delhi: Nearly 29% of products available in India’s local markets are perceived by consumers to be counterfeit, highlighting the growing challenge of fake goods across critical sectors, including pharmaceuticals…

Culture reports reveal bacteria damaged cornea of five patients from Kuchaman

Jaipur: Culture reports confirmed that five patients shifted to SMS Hospital, Jaipur, after cataract surgery at Kuchaman govt hospital have tested positive for serious postoperative eye infections caused by Enterobacter…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Nearly Three in Ten Products in Indian Local Markets Perceived as Counterfeit; Pharmaceuticals and FMCG among Worst-Affected Sectors: ASPA–CRISIL Intelligence Report

Nearly Three in Ten Products in Indian Local Markets Perceived as Counterfeit; Pharmaceuticals and FMCG among Worst-Affected Sectors: ASPA–CRISIL Intelligence Report

Culture reports reveal bacteria damaged cornea of five patients from Kuchaman

Culture reports reveal bacteria damaged cornea of five patients from Kuchaman

FSSAI prohibits Dabur from selling food products with ‘100%’ claims

FSSAI prohibits Dabur from selling food products with ‘100%’ claims

ORSL reinforces its commitment to improve diarrhoeal prevention in children

ORSL reinforces its commitment to improve diarrhoeal prevention in children

‘Donors got mixer grinders, cash’: blood banks in Bengal under scanner over ‘illegal’ sale to other States

‘Donors got mixer grinders, cash’: blood banks in Bengal under scanner over ‘illegal’ sale to other States

CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University

CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University